Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE1
Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers
- Status
- WITHDRAWN
- Phase
- PHASE1
Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE2
64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression
- Status
- WITHDRAWN
- Phase
- PHASE1
Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
- Status
- TERMINATED
- Phase
- PHASE2
Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2